<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470678</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002A2304</org_study_id>
    <nct_id>NCT00470678</nct_id>
  </id_info>
  <brief_title>EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)</brief_title>
  <official_title>An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5 mg) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Over 12 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate efficacy and safety for monthly ranibizumab 0.5 mg intravitreal
      injections in Asian patients with subfoveal choroidal neovascularization secondary to
      age-related macular degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in best-corrected visual acuity (BCVA) from Baseline, Month 4 and Month 12 as assessed with ETDRS (Early Treatment for Diabetic Retinopathy Study)-like charts at a distance of four meters</measure>
    <time_frame>Baseline, Month 4 and Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the retinal structure from baseline as assessed by fundus photography and fluorescein angiography, Month 4 and Month 12</measure>
    <time_frame>Month 4 and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety by rates of adverse events and serious adverse events, ophthalmic examinations, tonometry, and vital signs, baseline, Month 4, Month 6 and Month 12</measure>
    <time_frame>Baseline, Month 4, Month 6 and Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Choroidal Neovascularization</condition>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>Lucentis, RFB002</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Asian patients 50 years of age or greater.

          -  Patients with primary or recurrent subfoveal CNV secondary to AMD, including those
             with predominantly classic, minimally classic or active occult lesions with no classic
             component.

          -  Patients who have a BCVA score between 73 and 24 letters (approximately 20/40 to
             20/320 Snellen equivalent), inclusively, in the study eye.

          -  Total area of CNV (including both classic and occult components) encompassed within
             the lesion must be &gt;= 50% of the total lesion area

          -  Total lesion area must be &lt;= 12 disc areas

        Exclusion Criteria:

          -  Patients who have in the fellow eye a Snellen equivalent below 20/200

          -  Presence of angioid streaks, presumed ocular histoplasmosis syndrome, myopia
             (exceeding -8 diopters), or CNV secondary to causes other than AMD in the study eye

          -  Subfoveal fibrosis or atrophy in the study eye

          -  Total area of CNV (including both classic and occult components) encompassed within
             the lesion must be &gt;= 50% of the total lesion area

          -  Total lesion area must be &lt;= 12 disc areas

          -  Vitreous hemorrhage, retinal tear or history of rhegmatogenous retinal detachment or
             macular hole (Stage 3 or 4) in the study eye.

          -  Active, or history of, ocular inflammation or infection in the study eye within the
             last 30 days prior to screening.

          -  Uncontrolled glaucoma in the study eye

          -  Treatment in the study eye with verteporfin, external-beam radiation therapy,
             subfoveal focal laser photocoagulation, vitrectomy, submacular surgery, or
             transpupillary thermotherapy within 30 days prior to screening

          -  Previous treatment with anti-angiogenic drugs (pegaptanib, ranibizumab, bevacizumab,
             anecortave acetate, corticosteroids, protein kinase C inhibitors, squalamine, siRNA,
             VEGF-Trap etc.) for neovascular AMD in the study eye. Treatment of the fellow eye is
             permitted if administered &gt; 30 days before screening.

          -  History of intraocular surgery in the study eye including pars plana vitrectomy,
             except for uncomplicated cataract surgery more than 60 days prior to screening

          -  History of YAG laser posterior capsulotomy in the study eye within 30 days prior to
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharma</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>LinKou</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2795</url>
    <description>Results for CRFB002A2304 from the Novartis Clinical Trials Website</description>
  </link>
  <results_reference>
    <citation>Kwon OW, Lee FL, Chung H, Lai CC, Sheu SJ, Yoon YH; EXTEND III study group. EXTEND III: efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD. Graefes Arch Clin Exp Ophthalmol. 2012 Oct;250(10):1467-76. doi: 10.1007/s00417-012-1970-3. Epub 2012 Mar 2.</citation>
    <PMID>22382503</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2007</study_first_submitted>
  <study_first_submitted_qc>May 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2007</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age-related</keyword>
  <keyword>macular</keyword>
  <keyword>degeneration</keyword>
  <keyword>AMD</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Anti-VEGF</keyword>
  <keyword>choroidal</keyword>
  <keyword>neovascularization</keyword>
  <keyword>CNV</keyword>
  <keyword>Asian patients</keyword>
  <keyword>Korea</keyword>
  <keyword>Taiwan</keyword>
  <keyword>associated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

